Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
The main hypothesis of the study is that Bezlotoxumab is well tolerated and effective in
 reducing the recurrence of ICD (Clostridium Difficile infection) in patients with a high risk
 of recurrence in the first episode of ICD.

 As a consequence, the number of readmissions and hospital stays, will be reduced in patients
 treated with Bezlotoxumab.
This is a comparative study of patients with a high risk of recurrence of ICD in the first
 episode, treated with Bezlotoxumab (together with standard ICD therapy), with patients with
 first episode of ICD from a paired retrospective cohort (1: 2) using a propensity score.
Inclusion Criteria:

 -  Patients who have granted the IC and who are going to comply with the study visits and
 procedures according to their life expectations.

 -  Patient ≥ 18 years of age

 -  Having a first episode of DCI and presenting an estimated recurrence risk greater than
 35%.

 Exclusion Criteria:

 -  Patients <18 years old

 -  Pregnant or lactating women

 -  Women of childbearing age who are not willing to use an appropriate contraceptive
 method (such as oral contraceptives, intrauterine device or contraceptive barrier
 method along with spermicide or surgical sterilization) during the study.

 -  Life expectancy less than 6 months

 -  Impossibility or serious difficulties of clinical follow-up

 -  Any digestive disease that, at the discretion of the researcher, makes it difficult to
 assess the response due to impaired bowel habits.

 -  Immunoglobulin treatment in the last 3 months

 -  Previous treatment with Bezlotoxumab

 -  Treatment with an experimental drug in the previous 30 days or participating or
 planning to participate in any other clinical trial with an experimental drug during
 the 12-week trial period.

 -  Anti- ICD treatment forecast for more than 14 days (eg vancomycin in descending
 pattern) for the current episode.

 -  Health center staff

 -  Direct family members of the research team